Brand and Other Names:Levitra, Staxyn ODT
Dosing & Uses
Dosage Forms & Strengths
tablet, film coated
tablet, orally disintegrating
Film-coated tablet: 10 mg PO ~1 hour before sexual activity; may be increased to 20 mg or reduced to 5 mg, depending on effectiveness and tolerance; not to exceed 1 dose/day
Orally disintegrating tablet (ODT): 10 mg PO placed on tongue ~1 hour before sexual activity; not to exceed 1 dose/day
10-mg ODT not interchangeable with 10-mg film-coated tablet; ODT provides higher systemic exposure at same dose; if higher or lower doses are required, film-coated tablet should be prescribed
Coadministration with strong CYP3A4 inhibitor
- Ketoconazole 200 mg/day or itraconazole 200 mg/day: Vardenafil dosage not to exceed 5 mg/day
- Ketoconazole 400 mg/day or itraconazole 400 mg/day: Vardenafil dosage not to exceed 2.5 mg/day
- Indinavir, saquinavir, atazanavir, or clarithromycin: Vardenafil dosage not to exceed 2.5 mg/day
- Ritonavir (600 mg q12hr): Vardenafil dosage not to exceed 2.5 mg/72 hr
Coadministration with moderate CYP3A4 inhibitor
- Erythromycin 500 mg q8hr: Vardenafil dosage not to exceed 5 mg/day
Coadministration with alpha blocker
- Stabilized on alpha-blocker therapy (eg, alfuzosin, terazosin, tamsulosin): 5 mg/day PO initially
- Stabilized on alpha-blocker therapy and taking moderate-to-strong CYP3A4 inhibitor: 2.5 mg/day PO initially
- Mild, moderate, severe impairment: Dosage adjustment not necessary
- Hemodialysis: Not recommended
- Child-Pugh class A: Dosage adjustment not necessary
- Child-Pugh class B: Film-coated tablet, 5 mg PO ~1 hour before sexual activity; not to exceed 10 mg once daily; ODT not recommended
- Child-Pugh class C: Not recommended
5 mg PO ~1 hour before sexual activity
AUC and Cmax increased by 39% and 21%, respectively, in elderly men (compared with men <45 years)
Serious - Use Alternative
Significant - Monitor Closely
Flulike syndrome (3%)
Back pain (2%)
Increased creatine phosphokinase (2%)
Myocardial infarction (MI)
Soluble guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension
Coadministration with nitrates
- Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors
- Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates
- A suitable time interval following PDE5 dosing for the safe administration of nitrates or nitric oxide donors has not been determined
Anatomic deformation of penis, cardiovascular disease, left ventricular outflow obstruction, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, multidrug antihypertensive regimens, retinitis pigmentosa, conditions predisposing to priapism, concomitant use of CYP3A4 inhibitors
Avoid in patients with congenital QT prolongation or those taking class IA or III antiarrhythmics
Use in combination with other treatment for erectile dysfunction has not been studied and is not recommended
Not to be taken with other phosphodiesterase (PDE)-5 inhibitors (eg, sildenafil, tadalafil)
Concomitant use of alpha blockers increases risk of hypotension
May increase risk of rare sudden vision loss attributed to nonarteritic ischemic optic neuropathy; if vision problems arise, discontinue, and contact physician
Risk of sudden hearing loss
Pregnancy & Lactation
Pregnancy category: B
Lactation: Unknown whether drug is distributed into breast milk; indicated for males
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Sexual stimulation causes nitric oxide to be released in corpus cavernosum, and nitric oxide activates guanylate cyclase, which in turn increases cyclic guanosine monophosphate (cGMP), thus causing smooth-muscle relaxation; PDE-5 inhibitors enhance smooth muscle-relaxing effects of nitric oxide in corpus cavernosum by inhibiting degradation of cGMP
Onset: 60 min
Peak plasma time: 30-120 min
Peak plasma concentration: 8-19% lower for ODT than for film-coated tablet
Protein bound: 95%
Vd: 208 L
Metabolized in liver by CYP3A4 and (in minor amounts) CYP2C9
Metabolites: M1 (active; plasma concentration 26% of parent compound)
Half-life: 3-6 hr
Total body clearance: 56 L/hr
Excretion: Feces (95%), urine (5%)
Oral tablet or orally disintegrating tablet
- Take about 60 minutes before sexual activity
- Maximum dosing frequency is one tablet per day
- May take with or without food
Orally disintegrating tablet
- Place on tongue where it will dissolve
- Do not swallow
- Take without liquid
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs